Pulse Biosciences, Inc. (NASDAQ:PLSE) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02.RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On March14, 2017, Pulse Biosciences, Inc. announced its financial
results for its fourth fiscal quarter and year ended December 31,
2016. A copy of the press release containing the announcement is
included as Exhibit 99.1 and is incorporated herein by reference.
This information, as well as Exhibit 99.1, is intended to be
furnished under Item2.02 of Form 8-K, Results of Operations and
Financial Condition and shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), nor incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in
such a filing.
|
ITEM9.01. |
FINANCIAL STATEMENTS AND EXHIBITS. |
|||||
|
(d) |
Exhibits. |
|||||
|
99.1 |
Press Release issued by Pulse Biosciences, Inc. dated |
|||||
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Pulse Biosciences, Inc. |
||
|
By: |
/s/ Brian B. Dow |
|
|
Brian B. Dows
Chief Financial Officer, Senior Vice President, Secretary (Principal Financial and Principal Accounting Officer) |
||
Date: March14, 2017
EXHIBIT INDEX
|
ch |
|||
|
Exhibit No. |
Description |
||
|
99.1 |
Press Release issued by Pulse Biosciences, Inc. dated |
||
About Pulse Biosciences, Inc. (NASDAQ:PLSE)
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes. Pulse Biosciences, Inc. (NASDAQ:PLSE) Recent Trading Information
Pulse Biosciences, Inc. (NASDAQ:PLSE) closed its last trading session up +0.37 at 21.00 with 990,816 shares trading hands.
